US-based biotechnology firm InterVenn Biosciences has reported positive results from the interim clinical trial for its ovarian cancer clinical decision tool.

The clinical validation trial is currently taking place in the US, Malaysia and the Philippines. The trial involves the participation of women from five ethnic groups, Caucasian, Indian, Chinese, Malaysian and Filipino, with an estimated completion date of April 2021.

The aim of the trial, InterVenn Ovarian Cancer Liquid Biopsy (VOCAL), is to confirm if the blood test is superior to the accuracy of existing approaches to differentiate between malignant and benign pelvic tumours, with a focus on early recognition of ovarian cancer.

Under the interim results, VOCAL, based on mass spectrometry data processed by artificial intelligence (AI) and machine learning-driven algorithm, marked better specificity and sensitivity as compared to the current ovarian cancer test, CA 125.

The VOCAL test analyses glycoproteomic signatures as highly accurate biomarkers for disease, in addition to advanced drug target discovery.

By combining AI and mass spectrometry, InterVenn’s technology leverages largely inaccessible content of glycoproteome for improvement of health care.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

InterVenn CEO Aldo Carrascoso said: “These interim results clearly demonstrate the power and performance of our AI and mass spectrometry platform. We were consistently able to differentiate malignant from benign tumours with unparalleled specificity and sensitivity using only a blood test, we’ve set a newer, much higher, standard for performance.”

“This performance means that we were able to detect not only the more common epithelial ovarian cancer but also rare ovarian cancer subtypes aside from non-ovarian primary cancers such as lung, colorectal and others.”

American Cancer Society reported that in 2019, 22,250 individuals were diagnosed with ovarian cancer while 13,980 died from the disease.

Meanwhile, InterVenn Biosciences has appointed Klaus Lindpaintner as its chief scientific and medical officer.

Klaus served through Pfizer as VP and global head of human genetics and computational biomedicine. He was also CSO at Thermo Fisher Scientific and senior VP and head of the Roche Center for Medical Genomics.